These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 38000453)

  • 1. The quasi-CRM shift method for partially ordered groups.
    Celum C; Horton BJ; Conaway M
    Contemp Clin Trials; 2024 Jan; 136():107400. PubMed ID: 38000453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Shift models for dose-finding in partially ordered groups.
    Horton BJ; Wages NA; Conaway MR
    Clin Trials; 2019 Feb; 16(1):32-40. PubMed ID: 30309262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-finding clinical trial design for ordinal toxicity grades using the continuation ratio model: an extension of the continual reassessment method.
    Van Meter EM; Garrett-Mayer E; Bandyopadhyay D
    Clin Trials; 2012 Jun; 9(3):303-13. PubMed ID: 22547420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling adverse event counts in phase I clinical trials of a cytotoxic agent.
    Muenz DG; Braun TM; Taylor JM
    Clin Trials; 2018 Aug; 15(4):386-397. PubMed ID: 29779418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of various continual reassessment method models for dose-escalation phase 1 oncology clinical trials: using real clinical data and simulation studies.
    James GD; Symeonides S; Marshall J; Young J; Clack G
    BMC Cancer; 2021 Jan; 21(1):7. PubMed ID: 33402104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continual reassessment method for dose escalation clinical trials in oncology: a comparison of prior skeleton approaches using AZD3514 data.
    James GD; Symeonides SN; Marshall J; Young J; Clack G
    BMC Cancer; 2016 Aug; 16(1):703. PubMed ID: 27581751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quasi-partial order continual reassessment method: Applying toxicity scores to cancer dose-finding drug combination trials.
    O'Connell NS; Wages NA; Garrett-Mayer E
    Contemp Clin Trials; 2023 Feb; 125():107050. PubMed ID: 36529437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new pragmatic design for dose escalation in phase 1 clinical trials using an adaptive continual reassessment method.
    North B; Kocher HM; Sasieni P
    BMC Cancer; 2019 Jun; 19(1):632. PubMed ID: 31242873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On the feasibility of pediatric dose-finding trials in small samples with information from a preceding trial in adults.
    Zocholl D; Wiesenfarth M; Rauch G; Kopp-Schneider A
    J Biopharm Stat; 2022 Sep; 32(5):652-670. PubMed ID: 34962850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-finding design for multi-drug combinations.
    Wages NA; Conaway MR; O'Quigley J
    Clin Trials; 2011 Aug; 8(4):380-9. PubMed ID: 21652689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proportional odds model for dose-finding clinical trial designs with ordinal toxicity grading.
    Van Meter EM; Garrett-Mayer E; Bandyopadhyay D
    Stat Med; 2011 Jul; 30(17):2070-80. PubMed ID: 21344472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using the time-to-event continual reassessment method in the presence of partial orders.
    Wages NA; Conaway MR; O'Quigley J
    Stat Med; 2013 Jan; 32(1):131-41. PubMed ID: 22806898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How to design a dose-finding study using the continual reassessment method.
    Wheeler GM; Mander AP; Bedding A; Brock K; Cornelius V; Grieve AP; Jaki T; Love SB; Odondi L; Weir CJ; Yap C; Bond SJ
    BMC Med Res Methodol; 2019 Jan; 19(1):18. PubMed ID: 30658575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of phase I dose-finding designs in clinical trials with monotonicity assumption violation.
    Abbas R; Rossoni C; Jaki T; Paoletti X; Mozgunov P
    Clin Trials; 2020 Oct; 17(5):522-534. PubMed ID: 32631095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bayesian interval-based oncology dose-finding design with repeated quasi-continuous toxicity model.
    Zhao D; Zhu J; Wang L
    Contemp Clin Trials; 2021 Mar; 102():106265. PubMed ID: 33418097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Borrowing historical information to improve phase I clinical trials using meta-analytic-predictive priors.
    Chen X; Zhang J; Jiang Q; Yan F
    J Biopharm Stat; 2022 Jan; 32(1):34-52. PubMed ID: 35594366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A simulation-free approach to assessing the performance of the continual reassessment method.
    Braun TM
    Stat Med; 2020 Dec; 39(30):4651-4666. PubMed ID: 32939800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Bayesian dose-finding design for outcomes evaluated with uncertainty.
    Schipper MJ; Yuan Y; Taylor JM; Ten Haken RK; Tsien C; Lawrence TS
    Clin Trials; 2021 Jun; 18(3):279-285. PubMed ID: 33884907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRM and partial order CRM with adaptive rescaling for dose-finding in immunotherapy trials with a continuous outcome.
    Saha PT; Fine JP; Ivanova A
    Stat Med; 2023 Jun; 42(14):2409-2419. PubMed ID: 37012897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel model of the continual reassessment method in Phase I trial.
    Zhang W; Lei W; Zhu X
    Sci Rep; 2023 Mar; 13(1):5047. PubMed ID: 36977709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.